Restricted accessResearch articleFirst published online 2023-09
Caffeine Expands the Cisplatin-Induced Cell Death by Strengthening eIF2α/ATF4/CHOP Signaling and Blocking Autophagic Flux in Human Prostate Cancer Cells
Platinum-based compound cisplatin is widely used in various tumors, whereas its usage against many types of cancer, including prostate, is limited because of poor targeting, dose-limiting toxicity, and acquired resistance. Caffeine (Cfn) is a purine alkaloid compound and is widely consumed. Until now, a growing body of data has shown that Cfn has anticancer properties and is suitable for use with conventional chemotherapeutics. Thus, there is a need to develop more effective therapeutic approaches. Herein, we assessed the possible synergistic effect of Cfn with cisplatin in prostate cancer cells.
Materials and Methods:
Cell proliferation was evaluated by WST-1 assay. Autophagy, ubiquitin-proteasome system, unfolded protein response, endoplasmic reticulum stress, apoptosis, epithelial–mesenchymal transition (EMT), and androgenic signal-related numerous protein levels were analyzed by immunoblotting. Nucleus formation and cell death-related alterations were examined by immunofluorescence microscopy. Colonial growth was evaluated with a colony formation assay.
Results:
We found that androgen-sensitive prostate adenocarcinoma LNCaP cells were more sensitive to Cfn than metastatic prostate cancer Du145 cells and healthy prostatic cells PNT1A. Cousage of cisplatin and Cfn exhibited an expanded anticancer effect by inducing eukaryotic initiation factor 2α (eIF2α)/activating transcription factor 4 (ATF4)/C/EBP Homologous Protein (CHOP) signaling and negatively regulating autophagic flux. Moreover, Cfn displayed anticancer effects, and cotreatment with cisplatin gradually enhanced these properties. Furthermore, Cfn reduced the EMT and c-Myc expression. Also, androgenic signaling was strongly restricted by the cotreatment of Cfn and cisplatin.
Conclusion:
Our results suggest that combining the usage of cisplatin with Cfn treatment may offer an advanced therapeutic approach to prostate cancer.
Get full access to this article
View all access options for this article.
References
1.
SchmidS, OmlinA, HiganoC, et al.Activity of platinum-based chemotherapy in patients with advanced prostate cancer with and without DNA repair gene aberrations. JAMA Netw Open, 2020; 3:e2021692; doi: 10.1001/jamanetworkopen.2020.21692
2.
BrownA, KumarS, TchounwouPB. Cisplatin-based chemotherapy of human cancers. J Cancer Sci Ther, 2019; 11(4):97.
3.
SwamiU, McFarlandTR, NussenzveigR, et al.Advanced prostate cancer: Treatment advances and future directions. Trends Cancer Res, 2020; 6:702–715; doi: 10.1016/j.trecan.2020.04.010
4.
AlmeidaAAP, NaghetiniCC, SantosVR, et al.Influence of natural coffee compounds, coffee extracts and increased levels of caffeine on the inhibition of Streptococcus mutans. Food Res Int, 2012; 49:459–461; doi: 10.1016/j.foodres.2012.07.026
5.
YouD-C, KimY-S, HaA-W, et al.Possible health effects of caffeinated coffee consumption on Alzheimer's disease and cardiovascular disease. Toxicol Res, 2011; 27:7–10; doi: 10.5487/TR.2011.27.1.007
6.
ChenX, ZhaoY, TaoZ, et al.Coffee consumption and risk of prostate cancer: A systematic review and meta-analysis. BMJ Open, 2021; 11:e038902; doi: 10.1136/bmjopen-2020-038902
7.
OsariemeED, ModupeDT, OluchukwuOP. The anticancer activity of caffeine—A review. Arch Clin Biomed Res, 2019; 3:326–342; doi: 10.26502/acbr.50170077
8.
StelzerKJ, KohW-J, KurtzH, et al.Caffeine consumption is associated with decreased severe late toxicity after radiation to the pelvis. Int J Radiat Oncol Biol Phys, 1994; 30:411–417; doi: 10.1016/0360-3016(94)90022-1
9.
DongS, KongJ, KongJ, et al.Low concentration of caffeine inhibits the progression of the hepatocellular carcinoma via Akt signaling pathway. Anticancer Agents Med Chem, 2015; 15:484–492; doi: 10.2174/1871520615666150209110832
10.
SartiniM, BragazziNL, SpagnoloAM, et al.Coffee consumption and risk of colorectal cancer: A systematic review and meta-analysis of prospective studies. Nutrients, 2019; 11:694; doi: 10.3390/nu11030694
11.
Salari-MoghaddamA, MilajerdiA, SurkanPJ, et al.Caffeine, type of coffee, and risk of ovarian cancer: A dose-response meta-analysis of prospective studies. J Clin Endocrinol Metab, 2019; 104:5349–5359; doi: 10.1210/jc.2019-00637
12.
KitamotoY, SakuraiH, MitsuhashiN, et al.Caffeine diminishes cytotoxic effects of paclitaxel on a human lung adenocarcinoma cell line. Cancer Lett, 2003; 191:101–107; doi: 10.1016/s0304-3835(02)00591-8
13.
PascuaSM, McGaheyGE, MaN, et al.Caffeine and cisplatin effectively targets the metabolism of a triple-negative breast cancer cell line assessed via Phasor-FLIM. Int J Mol Sci, 2020; 21:2443;doi: 10.3390/ijms21072443
14.
VerfaillieT, SalazarM, VelascoG, et al.Linking ER stress to autophagy: Potential implications for cancer therapy. Int J Cell Biol, 2010; 2010:930509; doi: 10.1155/2010/930509
15.
YanM-M, NiJ-D, SongD, et al.Interplay between unfolded protein response and autophagy promotes tumor drug resistance. Oncol Lett, 2015; 10:1959–1969; doi: 10.3892/ol.2015.3508
16.
ChangH, ZouZ. Targeting autophagy to overcome drug resistance: Further developments. J Hematol Oncol, 2020; 13:159; doi: 10.1186/s13045-020-01000-2
17.
YunCW, LeeSH. The roles of autophagy in cancer. Int J Mol Sci, 2018; 19:3466; doi: 10.3390/ijms19113466
18.
Masclaux-DaubresseC, ChenQ, HavéM. Regulation of nutrient recycling via autophagy. Curr Opin Plant Biol, 2017; 39:8–17; doi: 10.1016/j.pbi.2017.05.001
ErdoganS, TurkekulK, SerttasR, et al.The natural flavonoid apigenin sensitizes human CD44+prostate cancer stem cells to cisplatin therapy. Biomed Pharmacother, 2017; 88:210–217; doi: 10.1016/j.biopha.2017.01.056
21.
LiuJ, ChenZ, GuoJ, et al.Ambra1 induces autophagy and desensitizes human prostate cancer cells to cisplatin. Biosci Rep, 2019; 39(8):BSR20170770; doi: 10.1042/BSR20170770
22.
JafariNK, VaziniH, GoodarziMT. The oxidative and cytotoxic effects of resveratrol compared with cisplatin in the LNCap prostate cancer cell line. Int J Basic Sci Med, 2022; 7:61–68; doi: 10.34172/ijbsm.2022.11
23.
YeX, ZhouX-J, ZhangH. Exploring the role of autophagy-related gene 5 (ATG5) yields important insights into autophagy in autoimmune/autoinflammatory diseases. Front Immunol, 2018; 9:2334; doi: 10.3389/fimmu.2018.02334
24.
YoshiiSR, MizushimaN. Monitoring and measuring autophagy. Int J Mol Sci, 2017; 18:1865; doi: 10.3390/ijms18091865
25.
CiechanoverA, SchwartzAL. The ubiquitin-proteasome pathway: the complexity and myriad functions of proteins death. Proc Natl Acad Sci U S A, 1998; 95:2727–2730; doi: 10.1073/pnas.95.6.2727
26.
JiCH, KwonYT. Crosstalk and interplay between the ubiquitin-proteasome system and autophagy. Mol Cells, 2017; 40(7):441–449; doi: 10.14348/molcells.2017.0115
27.
StormM, ShengX, ArnoldussenYJ, et al.Prostate cancer and the unfolded protein response. Oncotarget, 2016; 7:54051–54066; doi: 10.18632/oncotarget.9912
28.
PällmannN, LivgårdM, TesikovaM, et al.Regulation of the unfolded protein response through ATF4 and FAM129A in prostate cancer. Oncogene, 2019; 38:6301–6318; doi: 10.1038/s41388-019-0879-2
29.
OyadomariS, MoriM. Roles of CHOP/GADD153 in endoplasmic reticulum stress. Cell Death Differ, 2004; 11:381–389; doi: 10.1038/sj.cdd.4401373
30.
SoldaniC, ScovassiAI. Poly(ADP-ribose) polymerase-1 cleavage during apoptosis: An update. Apoptosis, 2002; 7:321–328; doi: 10.1023/a:1016119328968
31.
MashimoM, OnishiM, UnoA, et al.The 89-kDa PARP1 cleavage fragment serves as a cytoplasmic PAR carrier to induce AIF-mediated apoptosis. J Biol Chem, 2021; 296:100046; doi: 10.1074/jbc.RA120.014479
32.
RocheJ. The epithelial-to-mesenchymal transition in cancer. Cancers, 2018; 10:52; doi: 10.3390/cancers10030079
33.
De Las RivasJ, BrozovicA, IzraelyS, et al.Cancer drug resistance induced by EMT: Novel therapeutic strategies. Arch Toxicol, 2021; 95:2279–2297; doi: 10.1007/s00204-021-03063-7
34.
ChenH, LiuH, QingG. Targeting oncogenic Myc as a strategy for cancer treatment. Signal Transduct Target Ther, 2018; 3(1):5; doi: 10.1038/s41392-018-0008-7
35.
HanahanD. Hallmarks of cancer: New dimensions. Cancer Discov, 2022; 12:31–46; doi: 10.1158/2159-8290.CD-21-1059
36.
PucciC, MartinelliC, CiofaniG. Innovative approaches for cancer treatment: Current perspectives and new challenges. Ecancer, 2019; 13:961; doi: 10.3332/ecancer.2019.961
37.
ZhouJ, KangY, ChenL, et al.The drug-resistance mechanisms of five platinum-based antitumor agents. Front Pharmacol, 2020; 11:343; doi: 10.3389/fphar.2020.00343
38.
DasariS, TchounwouPB. Cisplatin in cancer therapy: Molecular mechanisms of action. Eur J Pharmacol, 2014; 740:364–378; doi: 10.1016/j.ejphar.2014.07.025
39.
International Agency for Research on Cancer. Chromium, nickel and welding. IARC monographs on the evaluation of carcinogenic risks to humans. 1990; 49:677.
40.
NawrotP, JordanS, EastwoodJ, et al.Effects of caffeine on human health. Food Addit Contam, 2003; 20(1):1–30; doi: 10.1080/0265203021000007840
41.
ToescuEC, O'NeillSC, PetersenOH, EisnerDA. Caffeine inhibits the agonist-evoked cytosolic Ca2+ signal in mouse pancreatic acinar cells by blocking inositol trisphosphate production. J Biol Chem, 1992; 267:23467–23470; doi: 10.1016/S0021-9258(18)35860-5
42.
Tariqul IslamAFM, ScavelloM, LotfiP, et al.Caffeine inhibits PI3K and mTORC2 in Dictyostelium and differentially affects multiple other cAMP chemoattractant signaling effectors. Mol Cell Biochem, 2019; 457:157–168; doi: 10.1007/s11010-019-03520-z
43.
MeisaprowP, AksornN, VinayanuwattikunC, et al.Caffeine induces G0/G1 cell cycle arrest and inhibits migration through integrin αv, β3, and FAK/Akt/c-Myc signaling pathway. Molecules, 2021; 26:7659; doi: 10.3390/molecules26247659
44.
DupontN, LeroyC, HamaïA, et al.Long-lived protein degradation during autophagy. Methods Enzymol, 2017; 31–40; doi: 10.1016/bs.mie.2016.09.074
45.
ChunY, KimJ. Autophagy: An essential degradation program for cellular homeostasis and life. Cells, 2018; 7:278; doi: 10.3390/cells7120278
46.
RozpedekW, PytelD, MuchaB, et al.The role of the PERK/eIF2α/ATF4/CHOP signaling pathway in tumor progression during endoplasmic reticulum stress. Curr Mol Med, 2016; 16:533–544; doi: 10.2174/1566524016666160523143937
47.
KangR, ZehHJ, LotzeMT, et al.The Beclin 1 network regulates autophagy and apoptosis. Cell Death Differ, 2011; 18:571–580; doi: 10.1038/cdd.2010.191
48.
BarsRL, Le BarsR, MarionJ, et al.ATG5 defines a phagophore domain connected to the endoplasmic reticulum during autophagosome formation in plants. Nat Commun, 2014; 5:4121; doi: 10.1038/ncomms5121
49.
NathS, DancourtJ, ShteynV, et al.Lipidation of the LC3/GABARAP family of autophagy proteins relies on a membrane-curvature-sensing domain in Atg3. Nat Cell Biol, 2014; 16:415–424; doi: 10.1038/ncb2940
50.
KocaturkNM, GozuacikD. Crosstalk between mammalian autophagy and the ubiquitin-proteasome system. Front Cell Dev Biol, 2018; 6:128; doi: 10.3389/fcell.2018.00128
51.
CorazzariM, GagliardiM, FimiaGM, et al.Endoplasmic reticulum stress, unfolded protein response, and cancer cell fate. Front Oncol, 2017; 7:78; doi: 10.3389/fonc.2017.00078
52.
FloreaA-M, BüsselbergD. Cisplatin as an anti-tumor drug: Cellular mechanisms of activity, drug resistance and induced side effects. Cancers, 2011; 3:1351–1371; doi: 10.3390/cancers3011351
53.
LohC-Y, ChaiJY, TangTF, et al.The E-cadherin and N-cadherin switch in epithelial-to-mesenchymal transition: Signaling, therapeutic implications, and challenges. Cells, 2019; 8:1118; doi: 10.3390/cells8101118
54.
VermaS, PrajapatiKS, KushwahaPP, et al.Resistance to second generation antiandrogens in prostate cancer: Pathways and mechanisms. Cancer Drug Resist, 2020; 3(4):742–761; doi: 10.20517/cdr.2020.45
55.
GumulecJ, BalvanJ, SztalmachovaM, et al.Cisplatin-resistant prostate cancer model: Differences in antioxidant system, apoptosis and cell cycle. Int J Oncol, 2014; 44:923–933; doi: 10.3892/ijo.2013.2223
56.
HillDP, HarperA, MalcolmJ, et al.Cisplatin-resistant triple-negative breast cancer subtypes: Multiple mechanisms of resistance. BMC Cancer, 2019; 19:1039; doi: 10.1186/s12885-019-6278-9
57.
ShenH, LiaoB, WanZ, et al.PTOV1 promotes cisplatin-induced chemotherapy resistance by activating the nuclear factor kappa B pathway in ovarian cancer. Mol Ther Oncolytics, 2021; 20:499–507; doi: 10.1016/j.omto.2021.02.008
58.
TalibWH, AlsayedAR, BarakatM, et al.Targeting drug chemo-resistance in cancer using natural products. Biomedicines, 2021; 9(10):1353; doi: 10.3390/biomedicines9101353
59.
CastañedaAM, MeléndezCM, UribeD, et al.Synergistic effects of natural compounds and conventional chemotherapeutic agents: Recent insights for the development of cancer treatment strategies. Heliyon, 2022; 8:e09519; doi: 10.1016/j.heliyon.2022.e09519
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
